GlassScriptPhysician profile
Joseph D Depietro
NPI 1215258272
$4,316.57
in general payments reported to CMS, 2019-2025
23 companies · $468 in 2025
The $468 reported for 2025 was more than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $582 · 2020: $680 · 2021: $615 · 2022: $597 · 2023: $827 · 2024: $548 · 2025: $468.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,843.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,843.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $945.65 | 2019-2025 | Nucala, Trelegy Ellipta |
| Optinose US, INC. | $773.76 | 2019-2025 | |
| Csl Behring | $513.67 | 2019-2021 | |
| Genzyme Corporation | $442.92 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $304.87 | 2020-2025 | Cuvitru |
| Astrazeneca Pharmaceuticals LP | $200.41 | 2019-2025 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $187.13 | 2021-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $180.03 | 2019-2024 | |
| Kaleo, INC. | $153.70 | 2019-2024 | Auvi-Q |
| Blueprint Medicines Corporation | $143.57 | 2023-2025 | Ayvakit |
| Shire North American Group INC | $76.99 | 2019 | |
| Hikma Pharmaceuticals USA | $63.92 | 2023-2024 | Ryaltris |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.06 | 2019-2022 | |
| Ars Pharmaceuticals Operations, INC. | $57.70 | 2025 | Neffy |
| Pfizer INC. | $40.31 | 2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $38.10 | 2020-2022 | |
| Precigen, INC. | $29.20 | 2025 | |
| Bio Products Laboratory USA, INC. | $23.66 | 2020 | |
| Horizon Therapeutics Plc | $18.05 | 2019 | |
| Pharming Healthcare, INC. | $17.71 | 2019 | |
| Medtronic, INC. | $16.51 | 2024 | Propel |
| Merck Sharp & Dohme LLC | $14.67 | 2023 | |
| Smith+Nephew, INC. | $12.98 | 2023 | Coblation, Rapid Rhino |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Depietro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.